NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO
Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly. (Click the title for the complete article)
Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy
Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione Regionale per la Ricerca Biomedica), Mr. Luigi Cajazzo, Managing director of FRRB and Mr. Massimiliano Amato, Board member of NMS Group SpA today. The delegation was warmly welcomed by Dr. Hugues Dolgos, the newly appointed CEO of NMS Group and CEOs of the Group’s subsidiaries Dr. Guoxian (Gregory) Wu, Mr. Angelo Colombo, and Mr. Giuseppe Vivolo. (Click the title for the complete article)
NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato.
Following the Shareholders’ Meeting, the Company’s newly formed Board of Directors approved a new governance to accelerate the progression of the portfolio, to strengthen the competitive positions of Accelera and NerPharMa, and to optimize and deliver concrete values for its patients, shareholders, employees and community. Dr. Hugues Dolgos, a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology, was appointed as Chief Executive Officer (“CEO”) of the Company, effective immediately. (Click the title to read the complete article)
Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021
Nerviano, 29 September 2021
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue. The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts and members of Pharma Tech Outlook’s editorial board, NMS Group has come on top in terms of its ability to innovate in drug R&D process, and to meet client requirements, through support and customization.
(Click the title for the complete article)
Nerviano, 6 May 2021 NerPharMa, a veteran CDMO with a specialization in oncology small molecule drug manufacture and a member of NMS Group, has announced today a Partnership Agreement with ICROM srl, aiming for collaboration on commercial production of High Potent...